載入中
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
前收盤價
US$13.74
−US$1.44 · -9.49%
盤中時間採用ET。市場資料可能有所延遲。
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
日內區間
目前US$13.74
52週區間
目前US$13.74
盤中時間採用ET。市場資料可能有所延遲。
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing several preclinical projects aimed at conditions like Alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis. The company also maintains various earlier-stage discovery initiatives focused on oncology. Eloxx Pharmaceuticals was established in 2013 and is headquartered in Watertown, Massachusetts.
日內區間
目前US$13.74
52週區間
目前US$13.74
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 635.9萬 USD | — | — | — |
| 銷貨成本 | — | — | — | 69.5萬 USD | 96萬 USD |
| 毛利 | — | 635.9萬 USD | — | −69.5萬 USD | −96萬 USD |
| 研究與開發 | 305.6萬 USD | 357.7萬 USD | 859.8萬 USD | 2372.7萬 USD | 2289.9萬 USD |
| 銷售、一般及管理費用 | 338.2萬 USD | 525萬 USD | 869萬 USD | 999.7萬 USD | 1848.9萬 USD |
| 營業費用 | 643.8萬 USD | 882.7萬 USD | 1728.8萬 USD | 3372.4萬 USD | 4138.8萬 USD |
| 利息收入 | 3.3萬 USD | 2.7萬 USD | 25.2萬 USD | 27.4萬 USD | 8000 USD |
| 利息支出 | 104.9萬 USD | 114.4萬 USD | 115.1萬 USD | 194.9萬 USD | 125.9萬 USD |
| 折舊和攤銷 | — | 16.4萬 USD | 80.9萬 USD | 69.5萬 USD | 96萬 USD |
| 營業利益 | −643.8萬 USD | −246.8萬 USD | −1728.8萬 USD | −3441.9萬 USD | −4234.8萬 USD |
| 淨利 | −599.5萬 USD | −314.3萬 USD | −1705.4萬 USD | −3606.5萬 USD | −6672.7萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$37.67
上漲空間 174.16%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年6月1日 | 1:11 | — | — |
股票分割 | 2022年12月2日 | 1:40 | — | — |
股票分割 | 2017年12月20日 | 1:20 | — | — |
股票分割 | 2013年10月21日 | 1:100 | — | — |
股票分割 | 1999年10月25日 | 2:1 | — | — |
已生效 2026年6月1日
1:11
已生效 2022年12月2日
1:40
已生效 2017年12月20日
1:20
已生效 2013年10月21日
1:100
已生效 1999年10月25日
2:1
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
